Patents by Inventor Kai Xie

Kai Xie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
    Patent number: 6949574
    Abstract: The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: September 27, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sing-Yuen Sit, Kai Xie, Hongfeng Deng
  • 3-Thia-4-arylquinolin-2-one potassium channel modulators
    Publication number: 20050176763
    Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome.
    Type: Application
    Filed: October 13, 2004
    Publication date: August 11, 2005
    Inventors: Kenneth Boy, Piyasena Hewawasam, Sing-Yuen Sit, Kai Xie
  • (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
    Publication number: 20050131032
    Abstract: The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.
    Type: Application
    Filed: January 19, 2005
    Publication date: June 16, 2005
    Inventors: Sing-Yuen Sit, Kai Xie, Hongfeng Deng
  • (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
    Publication number: 20030195226
    Abstract: The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.
    Type: Application
    Filed: February 4, 2003
    Publication date: October 16, 2003
    Inventors: Sing-Yuen Sit, Kai Xie, Hongfeng Deng
  • Bisarylimidazolyl fatty acid amide hydrolase inhibitors
    Patent number: 6562846
    Abstract: The present invention relates to bisarylimidazolyl derivatives and pharmaceutical compositions comprising said compounds inhibiting fatty acid amide hydrolase and useful for the treatment of pain, particularly neuropathic pain, psychomotor disorder, hypertension, cardiovascular disease, eating disorder, nausea, AIDS-related complex, glaucoma, inflammation, psoriasis or multiple sclerosis, and other conditions the treatment of which can be effected by inhibiting fatty acid amide hydrolase.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: May 13, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sing-Yuen Sit, Kai Xie
  • Bisarylimidazolyl fatty acid amide hydrolase inhibitors
    Publication number: 20020188009
    Abstract: The present invention relates to bisarylimidazolyl derivatives and pharmaceutical compositions comprising said compounds inhibiting fatty acid amide hydrolase and useful for the treatment of pain, particularly neuropathic pain, psychomotor disorder, hypertension, cardiovascular disease, eating disorder, nausea, AIDS-related complex, glaucoma, inflammation, psoriasis or multiple sclerosis, and other conditions the treatment of which can be effected by inhibiting fatty acid amide hydrolase.
    Type: Application
    Filed: April 23, 2002
    Publication date: December 12, 2002
    Inventors: Sing-Yuen Sit, Kai Xie